Regulatory aspects of small molecule drugs for heart regeneration

Advanced Drug Delivery Reviews

Volumn 96, Issue , 2016, Pages 245-252

  Rodgers, Kathleen ^a   Papinska, Anna ^a   Mordwinkin, Nicholas ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MILTENYI BIOTEC GMBH   (Germany)

Author keywords

Cardiac; IPSC generated cardiomyocytes; Regeneration; Regulatory; Small molecule

Indexed keywords

DISEASES; MOLECULES; STEM CELLS; SYNTHESIS (CHEMICAL);

CARDIAC; CARDIOMYOCYTES; REGENERATION; REGULATORY; SMALL MOLECULES;

HEART;

3,5 ISOXAZOLE; 7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; BETA CATENIN; CARDIAC AGENT; CARDIONOGEN; CYCLOOXYGENASE 2; DIPEPTIDYL PEPTIDASE IV; DIPROTIN A; G PROTEIN COUPLED RECEPTOR; GPR68 PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; ISOXAZOLE DERIVATIVE; ISX 1; ITD 1; LENOGRASTIM; N BENZYL 1,2,3,4,8,9 HEXAHYDRO 6 (4 HYDROXYBENZYL) 8 (1 NAPHTHYLMETHYL) 4,7 DIOXO 2H PYRAZINO[1,2 A]PYRIMIDINE 1(6H) CARBOXAMIDE; PROSTAGLANDIN; PROSTAGLANDIN E2; PYRVINIUM EMBONATE; SITAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; MOLECULAR LIBRARY;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CONGESTIVE CARDIOMYOPATHY; DRUG CONTROL; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; ENDOTHELIAL PROGENITOR CELL; FOOD AND DRUG ADMINISTRATION; HEART; HEART DEVELOPMENT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE REVASCULARIZATION; HEART REGENERATION; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TISSUE REGENERATION; WNT SIGNALING PATHWAY; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASES; CYTOLOGY; DRUG EFFECTS; GOVERNMENT REGULATION; INDUCED PLURIPOTENT STEM CELL; LEGISLATION AND JURISPRUDENCE; MOLECULAR LIBRARY; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; REGENERATION; THERAPEUTIC USE; UNITED STATES;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GOVERNMENT REGULATION; HEART; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; REGENERATION; SMALL MOLECULE LIBRARIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84951787837     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.06.013     Document Type: Review

References (107)

1. World Health Organization [online] Available from:, (Accessed on: May 5th 2015). http://www.who.int/mediacentre/factsheets/fs317/en/.
2. Kikuchi K., Poss K.D. Cardiac regenerative capacity and mechanisms. Annu. Rev. Cell Dev. Biol. 2012, 28:719-741. 10.1146/annurev-cellbio-101011-155739.
3. Segers V.F.M., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 451:937-942. 10.1038/nature06800.
4. Garbern J.C., Lee R.T. Cardiac stem cell therapy and the promise of heart regeneration. Stem Cells 2013, 12:689-698. 10.1016/j.stem.2013.05.008.
5. Federal Code of Regulations SECTION 2003, 201. [21 U.S.C. 321], Section (g)1.
6. Food and Drug Administration [online] Available from:, (Accessed on: May 5th 2015). http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm.
7. Food and Drug Administration [online] Available from:, (Accessed on May 5th 2015). http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/default.htm.
8. DiMasi J.A., Feldman L., Seckler A., Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 2010, 87:272-277. 10.1038/clpt.2009.295.
9. Lin J.H. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 1995, 23:1008-1021.
10. Tibbitts J. Issues related to the use of canines in toxicologic pathology-issues with pharmacokinetics and metabolism. Toxicol. Pathol. 2003, 31:17-24. (Suppl.).
11. Walker D.K. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br. J. Clin. Pharmacol. 2004, 58:601-608. 10.1111/j.1365-2125.2004.02194.x.
12. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
13. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov. 2011, 10:328-329. 10.1038/nrd3439.
14. Plenge R.M., Scolnick E.M., Altshuler D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 2013, 12:581-594. 10.1038/nrd4051.
15. Hackam D.G., Redelmeier D.A. Translation of research evidence from animals to humans. JAMA 2006, 296:1731-1732. 10.1001/jama.296.14.1731.
16. Henderson V.C., Kimmelman J., Fergusson D., Grimshaw J.M., Hackam D.G. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med. 2013, 10:e1001489.
17. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007, 26:1-13. 10.1016/j.nbd.2006.12.015.
18. Sena E., van der Worp H.B., Howells D., Macleod M. How can we improve the pre-clinical development of drugs for stroke?. Trends Neurosci. 2007, 30:433-439. 10.1016/j.tins.2007.06.009.
19. Steward O., Popovich P.G., Dietrich W.D., Kleitman N. Replication and reproducibility in spinal cord injury research. Exp. Neurol. 2012, 233:597-605. 10.1016/j.expneurol.2011.06.017.
20. van Berlo J.H., Kanisicak O., Maillet M., Vagnozzi R.J., Karch J., Lin S.-C.J., et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 2014, 509:337-341. 10.1038/nature13309.
21. Senyo S.E., Steinhauser M.L., Pizzimenti C.L., Yang V.K., Cai L., Wang M., et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 2013, 493:433-436. 10.1038/nature11682.
22. Howe L.R., Brown A. Wnt signaling in breast cancer. Cancer Biol. Ther. 2004, 3:36-41.
23. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850. 10.1038/nature03319.
24. Tian Y., Cohen E.D., Morrisey E.E. The importance of Wnt signaling in cardiovascular development. Pediatr. Cardiol. 2010, 31:342-348. 10.1007/s00246-009-9606-z.
25. Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 2003, 10:55-63. 10.1038/nm979.
26. Chen B., Dodge M.E., Tang W., Lu J., Ma Z., Fan C.-W., et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 2009, 5:100-107. 10.1038/nchembio.137.
27. Qyang Y., Martin-Puig S., Chiravuri M., Chen S., Xu H., Bu L., et al. The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. Cell Stem Cell 2007, 1:165-179. 10.1016/j.stem.2007.05.018.
28. Lanier M., Schade D., Willems E., Tsuda M., Spiering S., Kalisiak J., et al. Wnt inhibition correlates with human embryonic stem cell cardiomyogenesis: a structure-activity relationship study based on inhibitors for the Wnt response. J. Med. Chem. 2012, 55:697-708. 10.1021/jm2010223.
29. Zelarayan L.C., Noack C., Sekkali B., Kmecova J., Gehrke C., Renger A., et al. Beta-catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19762-19767. 10.1073/pnas.0808393105.
30. van de Schans V.A.M., van den Borne S.W.M., Strzelecka A.E., Janssen B.J.A., van der Velden J.L.J., Langen R.C.J., et al. Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy. Hypertension 2007, 49:473-480. 10.1161/01.HYP.0000255946.55091.24.
31. Saraswati S., Alfaro M.P., Thorne C.A., Atkinson J., Lee E., Young P.P. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS ONE 2010, 5:e15521. 10.1371/journal.pone.0015521.s003.
32. Murakoshi M., Saiki K., Urayama K., Sato T.N. An anthelmintic drug, pyrvinium pamoate, thwarts fibrosis and ameliorates myocardial contractile dysfunction in a mouse model of myocardial infarction. PLoS ONE 2013, 8:e79374. 10.1371/journal.pone.0079374.g008.
33. Emami K.H., Nguyen C., Ma H., Kim D.H., Jeong K.W., Eguchi M., et al. A small molecule inhibitor of b-catenin/CREB-binding protein transcription. PNAS 2004, 101:12682-12687.
34. Sasaki T., Hwang H., Nguyen C., Kloner R.A., Kahn M. The small molecule Wnt signaling modulator ICG-001 improves contractile function in chronically infarcted rat myocardium. PLoS ONE 2013, 8:e75010. 10.1371/journal.pone.0075010.s005.
35. Ni T.T., Rellinger E.J., Mukherjee A., Xie S., Stephens L., Thorne C.A., et al. Discovering small molecules that promote cardiomyocyte generation by modulating Wnt signaling. Chem. Biol. 2011, 18:1658-1668. 10.1016/j.chembiol.2011.09.015.
36. Naito A.T., Shiojima I., Akazawa H., Hidaka K., Morisaki T., Kikuchi A., et al. Developmental stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogenesis and hematopoiesis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19812-19817. 10.1073/pnas.0605768103.
37. Paige S.L., Osugi T., Afanasiev O.K., Pabon L., Reinecke H., Murry C.E. Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS ONE 2010, 5:e11134. 10.1371/journal.pone.0011134.
38. Lian X., Hsiao C., Wilson G., Zhu K., Hazeltine L.B., Azarin S.M., et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1848-E1857. 10.1073/pnas.1200250109.
39. Willems E., Cabral-Teixeira J., Schade D., Cai W., Reeves P., Bushway P.J., et al. Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell 2012, 11:242-252. 10.1016/j.stem.2012.04.025.
40. Schade D., Lanier M., Willems E., Okolotowicz K., Bushway P., Wahlquist C., et al. Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling. J. Med. Chem. 2012, 55:9946-9957. 10.1021/jm301144g.
41. Akhurst R.J., Hata A. Targeting the TGFβ signalling pathway in disease. Nat. Publ. Group 2012, 11:790-811. 10.1038/nrd3810.
42. Scott I.C. Life before Nkx2.5: cardiovascular progenitor cells: embryonic origins and development. Curr. Top. Dev. Biol. 2012, 100:1-31. 10.1016/B978-0-12-387786-4.00001-4.
43. Russell J.L., Goetsch S.C., Aguilar H.R., Frantz D.E., Schneider J.W. Targeting native adult heart progenitors with cardiogenic small molecules. ACS Chem. Biol. 2012, 7:1067-1076. 10.1021/cb200525q.
44. Russell J.L., Goetsch S.C., Gaiano N.R., Hill J.A., Olson E.N., Schneider J.W. A dynamic notch injury response activates epicardium and contributes to fibrosis repair. Circ. Res. 2011, 108:51-59. 10.1161/CIRCRESAHA.110.233262.
45. Russell J.L., Goetsch S.C., Aguilar H.R., Coe H., Luo X., Liu N., et al. Regulated expression of pH sensing G protein-coupled receptor-68 identified through chemical biology defines a new drug target for ischemic heart disease. ACS Chem. Biol. 2012, 7:1077-1083. 10.1021/cb300001m.
46. Kubasiak L.A., Hernandez O.M., Bishopric N.H., Webster K.A. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12825-12830. 10.1073/pnas.202474099.
47. Degousee N., Fazel S., Angoulvant D., Stefanski E., Pawelzik S.-C., Korotkova M., et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008, 117:1701-1710. 10.1161/CIRCULATIONAHA.107.749739.
48. Wang D., Patel V.V., Ricciotti E., Zhou R., Levin M.D., Gao E., et al. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. PNAS 2009, 106:7548-7552. 10.1073/pnas.0805806106.
49. 2 promotes post-infarction cardiomyocyte replenishment by endogenous stem cells. EMBO Mol. Med. 2014, 6:496-503. 10.1002/emmm.201303687.
50. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308. 10.1136/bmj.332.7553.1302.
51. Nakamura K., Sata M., Iwata H., Sakai Y., Hirata Y., Kugiyama K., et al. A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin. Sci. 2007, 112:607-616. 10.1042/CS20060301.
52. Ishimaru K., Miyagawa S., Fukushima S., Saito A., Sakai Y., Ueno T., et al. Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: a promising regenerative therapy for the failing heart. J. Thorac. Cardiovasc. Surg. 2013, 146:1516-1525. 10.1016/j.jtcvs.2013.02.045.
53. Hazekawa M., Morihata K., Yoshida M., Sakai Y., Uchida T. The angiogenic effect of ONO-1301, a novel long-acting prostacyclin agonist loaded in PLGA microspheres prepared using different molecular weights of PLGA, in a murine sponge model. Drug Dev. Ind. Pharm. 2014, 40:1435-1442. 10.3109/03639045.2013.828220.
54. Zaruba M.-M., Theiss H.D., Vallaster M., Mehl U., Brunner S., David R., et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009, 4:313-323. 10.1016/j.stem.2009.02.013.
55. Theiss H.D., Gross L., Vallaster M., David R., Brunner S., Brenner C., et al. Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction. Int. J. Cardiol. 2013, 168:3359-3369. 10.1016/j.ijcard.2013.04.121.
56. Theiss H.D., Brenner C., Engelmann M.G., Zaruba M.-M., Huber B., Henschel V., et al. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)-rationale, design and first interim analysis. Int. J. Cardiol. 2010, 145:282-284. 10.1016/j.ijcard.2009.09.555.
57. Santos R.A.S., Simoes e Silva A.C., Maric C., Silva D.M.R., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8258-8263. 10.1073/pnas.1432869100.
58. Rabelo L.A., Alenina N., Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens. Res. 2011, 34:154-160. 10.1038/hr.2010.235.
59. Simões e Silva A.C., Silveira K.D., Ferreira A.J., Teixeira M.M. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol. 2013, 169:477-492. 10.1111/bph.12159.
60. Rodgers K.E., Xiong S., diZerega G.S. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother. Pharmacol. 2002, 49:403-411. 10.1007/s00280-002-0434-6.
61. Rodgers K.E., Oliver J., diZerega G.S. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother. Pharmacol. 2006, 57:559-568. 10.1007/s00280-005-0078-4.
62. Beyer A.M., Guo D.-F., Rahmouni K. Prolonged treatment with angiotensin 1-7 improves endothelial function in diet-induced obesity. J. Hypertens. 2013, 31:730-738. 10.1097/HJH.0b013e32835ecbe5.
63. Iusuf D., Henning R.H., van Gilst W.H., Roks A.J.M. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur. J. Pharmacol. 2008, 585:303-312. 10.1016/j.ejphar.2008.02.090.
64. Xu P., Costa-Goncalves A.C., Todiras M., Rabelo L.A., Sampaio W.O., Moura M.M., et al. Endothelial dysfunction and elevated blood pressure in Mas gene-deleted mice. Hypertension 2008, 51:574-580. 10.1161/HYPERTENSIONAHA.107.102764.
65. Loot A.E., Roks A.J.M., Henning R.H., Tio R.A., Suurmeijer A.J.H., Boomsma F., et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002, 105:1548-1550. 10.1161/01.CIR.0000013847.07035.B9.
66. Wang Y., Qian C., Roks A.J.M., Westermann D., Schumacher S.-M., Escher F., et al. Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ. Heart Fail. 2010, 3:286-293. 10.1161/CIRCHEARTFAILURE.109.905968.
67. Qi Y., Bruce E., Shenoy V., Vohra R., Cole-Jeffrey C., Abbatematteo J., et al. Angiotensin-(1-7) improves engraftment and reparative potential of cardiac progenitor cells in a rat model of myocardial infarction (1180.17). FASEB J. 2014, 28.
68. Sampaio W.O., Souza dos Santos R.A., Faria-Silva R., da Mata Machado L.T., Schiffrin E.L., Touyz R.M. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2006, 49:185-192. 10.1161/01.HYP.0000251865.35728.2f.
69. Aicher A., Heeschen C., Mildner-Rihm C., Urbich C., Ihling C., Technau-Ihling K., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 2003, 9:1370-1376. 10.1038/nm948.
70. Sampaio W.O., Henrique de Castro C., Santos R.A.S., Schiffrin E.L., Touyz R.M. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007, 50:1093-1098. 10.1161/HYPERTENSIONAHA.106.084848.
71. Shuaib A., Lees K.R., Lyden P., Grotta J., Davalos A., Davis S.M., et al. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 2007, 357:562-571. 10.1056/NEJMoa070240.
72. Sena E.S., van der Worp H.B., Bath P.M.W., Howells D.W., Macleod M.R. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010, 8:e1000344. 10.1371/journal.pbio.1000344.
73. van der Worp H.B., Howells D.W., Sena E.S., Porritt M.J., Rewell S., O'Collins V., et al. Can animal models of disease reliably inform human studies?. PLoS Med. 2010, 7:e1000245. 10.1371/journal.pmed.1000245.
74. Lompre A.M., Mercadier J.J., Wisnewsky C., Bouveret P., Pantaloni C., D'Albis A., et al. Species- and age-dependent changes in the relative amounts of cardiac myosin isoenzymes in mammals. Dev. Biol. 1981, 84:286-290.
75. Nolan G.P. What's wrong with drug screening today. Nat. Chem. Biol. 2007, 3:187-191. 10.1038/nchembio0407-187.
76. Sams-Dodd F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov. Today 2013, 18:211-217. 10.1016/j.drudis.2012.10.010.
77. Sams-Dodd F. Target-based drug discovery: is something wrong?. Drug Discov. Today 2005, 10:139-147. 10.1016/S1359-6446(04)03316-1.
78. Kannankeril P.J., Roden D.M. Drug-induced long QT and Torsade de Pointes: recent advances. Curr. Opin. Cardiol. 2007, 22:39-43.
79. Laverty H., Benson C., Cartwright E., Cross M., Garland C., Hammond T., et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br. J. Pharmacol. 2011, 163:675-693. 10.1111/j.1476-5381.2011.01255.x.
80. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872. 10.1016/j.cell.2007.11.019.
81. Mordwinkin N.M., Burridge P.W., Wu J.C. A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards. J. Cardiovasc. Transl. Res. 2013, 6:22-30. 10.1007/s12265-012-9423-2.
82. Mordwinkin N.M., Lee A.S., Wu J.C. Patient-specific stem cells and cardiovascular drug discovery. JAMA 2013, 310:2039-2040. 10.1001/jama.2013.282409.
83. Carvajal-Vergara X., Sevilla A., D'Souza S.L., Ang Y.-S., Schaniel C., Lee D.-F., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010, 465:808-812. 10.1038/nature09005.
84. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flugel L., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 2010, 363:1397-1409. 10.1056/NEJMoa0908679.
85. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., Winterstern A., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471:225-229. 10.1038/nature09747.
86. Yazawa M., Hsueh B., Jia X., Pasca A.M., Bernstein J.A., Hallmayer J., et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011, 471:230-234. 10.1038/nature09855.
87. Xi B., Wang T., Li N., Ouyang W., Zhang W., Wu J., et al. Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System. J. Lab. Autom. 2011, 16:415-421. 10.1016/j.jala.2011.09.002.
88. Abassi Y.A., Xi B., Li N., Ouyang W., Seiler A., Watzele M., et al. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br. J. Pharmacol. 2012, 165:1424-1441. 10.1111/j.1476-5381.2011.01623.x.
89. Barbaric I., Gokhale P.J., Andrews P.W. High-content screening of small compounds on human embryonic stem cells. Biochem. Soc. Trans. 2010, 38:1046-1050. 10.1042/BST0381046.
90. McNeish J., Roach M., Hambor J., Mather R.J., Weibley L., Lazzaro J., et al. High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors. J. Biol. Chem. 2010, 285:17209-17217. 10.1074/jbc.M109.098814.
91. Desbordes S.C., Studer L. Adapting human pluripotent stem cells to high-throughput and high-content screening. Nat. Protoc. 2013, 8:111-130. 10.1038/nprot.2012.139.
92. Burridge P.W., Matsa E., Shukla P., Lin Z.C., Churko J.M., Ebert A.D., et al. Chemically defined generation of human cardiomyocytes. Nat. Methods 2014, 11:855-860. 10.1038/nmeth.2999.
93. Dunlop J., Bowlby M., Peri R., Vasilyev D., Arias R. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat. Rev. Drug Discov. 2008, 7:358-368. 10.1038/nrd2552.
94. Mathur A., Loskill P., Shao K., Huebsch N., Hong S., Marcus S.G., et al. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci. Rep. 2015, 5:8883. 10.1038/srep08883.
95. Stoelzle S., Haythornthwaite A., Kettenhofen R., Kolossov E., Bohlen H., George M., et al. Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction. J. Biomol. Screen. 2011, 16:910-916. 10.1177/1087057111413924.
96. Asai Y., Tada M., Otsuji T.G., Nakatsuji N. Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: an ideal hybrid model assay for drug development. Curr. Stem Cell Res. Ther. 2010, 5:227-232.
97. Cerignoli F., Charlot D., Whittaker R., Ingermanson R., Gehalot P., Savchenko A., et al. High throughput measurement of Ca(2)(+) dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J. Pharmacol. Toxicol. Methods 2012, 66:246-256. 10.1016/j.vascn.2012.08.167.
98. Sirenko O., Crittenden C., Callamaras N., Hesley J., Chen Y.-W., Funes C., et al. Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J. Biomol. Screen. 2013, 18:39-53. 10.1177/1087057112457590.
99. Agarwal A., Goss J.A., Cho A., McCain M.L., Parker K.K. Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip 2013, 13:3599-3608. 10.1039/c3lc50350j.
100. McCain M.L., Sheehy S.P., Grosberg A., Goss J.A., Parker K.K. Recapitulating maladaptive, multiscale remodeling of failing myocardium on a chip. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:9770-9775. 10.1073/pnas.1304913110.
101. Pointon A., Abi-Gerges N., Cross M.J., Sidaway J.E. Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. Toxicol. Sci. 2013, 132:317-326. 10.1093/toxsci/kft005.
102. Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., Hassink R., et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003, 107:2733-2740.
103. Germanguz I., Sedan O., Zeevi-Levin N., Shtrichman R., Barak E., Ziskind A., et al. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J. Cell. Mol. Med. 2011, 15:38-51. 10.1111/j.1582-4934.2009.00996.x.
104. Rana P., Anson B., Engle S., Will Y. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicol. Sci. 2012, 130:117-131. 10.1093/toxsci/kfs233.
105. Nunes S.S., Miklas J.W., Liu J., Aschar-Sobbi R., Xiao Y., Zhang B., et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat. Methods 2013, 10:781-787. 10.1038/nmeth.2524.
106. Tulloch N.L., Muskheli V., Razumova M.V., Korte F.S., Regnier M., Hauch K.D., et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ. Res. 2011, 109:47-59. 10.1161/CIRCRESAHA.110.237206.
107. Feinberg A.W., Alford P.W., Jin H., Ripplinger C.M., Werdich A.A., Sheehy S.P., et al. Controlling the contractile strength of engineered cardiac muscle by hierarchal tissue architecture. Biomaterials 2012, 33:5732-5741. 10.1016/j.biomaterials.2012.04.043.